Lower urinary tract symptoms · 2026
Pretreatment Factors Associated With Pain Improvement After Cernitin Pollen Extract Therapy in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Post Hoc Analysis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Matsukawa Yoshihisa, Naito Yushi, Inoue Satoshi, Kimura Tomokazu, Gotoh Momokazu, Akamatsu Shusuke
Аннотация
OBJECTIVES: Cernitin pollen extract is used for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), but pretreatment factors associated with pain improvement remain unclear. This study explored baseline factors associated with clinically meaningful pain relief after cernitin therapy in men with CP/CPPS.
METHODS: This exploratory post hoc analysis was based on a single-center, open-label, randomized prospective trial conducted between July 2017 and December 2018. Men with persistent CP/CPPS despite at least 12 weeks of α1-blocker therapy were randomized to receive add-on cernitin pollen extract or tadalafil for 12 weeks. The present analysis included 42 men assigned to cernitin. Good responders were defined as patients with a ≥ 50% improvement in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) pain subscore. Baseline variables were compared, and exploratory logistic regression analysis with a limited number of covariates was performed.
RESULTS: Among 42 patients, 21 were good responders and 21 were poor responders. The NIH-CPSI pain subscore improved by 67.0% in good responders and by 28.9% in poor responders (p < 0.001). Baseline serum total testosterone was significantly lower in good responders than in poor responders (4.5 ± 2.9 vs. 6.3 ± 2.4 ng/mL; p = 0.006). In exploratory multivariable analysis, lower serum total testosterone remained the only factor associated with clinically meaningful pain improvement (odds ratio 0.53, 95% confidence interval 0.30-0.95; p = 0.033).
CONCLUSIONS: Lower pretreatment serum total testosterone was associated with clinically meaningful pain improvement after cernitin therapy. These findings are hypothesis-generating and require validation in larger prospective cohorts.
METHODS: This exploratory post hoc analysis was based on a single-center, open-label, randomized prospective trial conducted between July 2017 and December 2018. Men with persistent CP/CPPS despite at least 12 weeks of α1-blocker therapy were randomized to receive add-on cernitin pollen extract or tadalafil for 12 weeks. The present analysis included 42 men assigned to cernitin. Good responders were defined as patients with a ≥ 50% improvement in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) pain subscore. Baseline variables were compared, and exploratory logistic regression analysis with a limited number of covariates was performed.
RESULTS: Among 42 patients, 21 were good responders and 21 were poor responders. The NIH-CPSI pain subscore improved by 67.0% in good responders and by 28.9% in poor responders (p < 0.001). Baseline serum total testosterone was significantly lower in good responders than in poor responders (4.5 ± 2.9 vs. 6.3 ± 2.4 ng/mL; p = 0.006). In exploratory multivariable analysis, lower serum total testosterone remained the only factor associated with clinically meaningful pain improvement (odds ratio 0.53, 95% confidence interval 0.30-0.95; p = 0.033).
CONCLUSIONS: Lower pretreatment serum total testosterone was associated with clinically meaningful pain improvement after cernitin therapy. These findings are hypothesis-generating and require validation in larger prospective cohorts.